StockMacro
Menu

Heartflow

$46.69 +64% in 6 monthsMarket cap $4.1B

HTFL on XNAS, Health Care, Heartflow, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue rose 57% to $72.9M but the company still lost $79M over 12 months.

  • BadFree cash flow was -$56.1M over the last 12 months
  • GoodInstitutional holders rose 29%, from 191 to 246 filers

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
843
Website
heartflow.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 17 Mar 2027 (an estimate: a year ago it reported on 18 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $72.9M, net loss $11.5M.
Quarter to 31 Mar 2024: revenue –, net income -$20.9MQuarter to 30 Jun 2024: revenue $31.1M, net income -$23.4MQuarter to 30 Jun 2024: revenue $31.1M, net income -$23.4MQuarter to 30 Sep 2024: revenue $32.9M, net income -$19.1MQuarter to 30 Sep 2024: revenue $32.9M, net income -$19.1MQuarter to 31 Dec 2024: revenue $35.0M, net income -$33.0MQuarter to 31 Dec 2024: revenue $35.0M, net income -$33.0MQuarter to 31 Mar 2025: revenue $37.2M, net income -$32.3MQuarter to 31 Mar 2025: revenue $37.2M, net income -$32.3MQuarter to 30 Jun 2025: revenue $43.4M, net income -$9.2MQuarter to 30 Jun 2025: revenue $43.4M, net income -$9.2MQuarter to 30 Sep 2025: revenue $46.3M, net income -$50.9MQuarter to 30 Sep 2025: revenue $46.3M, net income -$50.9MQuarter to 31 Dec 2025: revenue $49.1M, net income -$24.4MQuarter to 31 Dec 2025: revenue $49.1M, net income -$24.4MQuarter to 31 Mar 2026: revenue $52.6M, net income -$27.4MQuarter to 31 Mar 2026: revenue $52.6M, net income -$27.4MQuarter to 30 Jun 2026: revenue $64.1M, net income -$15.7MQuarter to 30 Jun 2026: revenue $64.1M, net income -$15.7MQuarter to 30 Sep 2026: revenue $72.9M, net income -$11.5MQuarter to 30 Sep 2026: revenue $72.9M, net income -$11.5M
31 Mar 2024RevenueNet incomeNet losstallest bar $72.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$72.9M-$11.5M
30 Jun 2026$64.1M-$15.7M
31 Mar 2026$52.6M-$27.4M
31 Dec 2025$49.1M-$24.4M
30 Sep 2025$46.3M-$50.9M
30 Jun 2025$43.4M-$9.2M
31 Mar 2025$37.2M-$32.3M
31 Dec 2024$35.0M-$33.0M
30 Sep 2024$32.9M-$19.1M
30 Jun 2024$31.1M-$23.4M
31 Mar 2024–-$20.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $238.7M $161.9M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +47% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$79.0M -$125.4M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 81.8% 75.6% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -33.1% -38.5% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -33.1% -77.4% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -29.4% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$56.1M -$60.9M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $253.0M $291.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $3.21
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 17.2 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 14.5 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
HeartflowHTFL (this company) $4.1Bloss17.2+47%-33.1%
ICU MedicalICUI $4.3B71.52.0-5.9%2.8%
MiniMedMMED $4.5Bloss1.4–-9.6%
Pulse BiosciencesPLSE $3.4Blossover 999+1637%–
Merit Medical SystemsMMSI $5.1B31.63.1+9.1%9.9%
iRhythmIRTC $3.2Bloss3.7+22%-4.5%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$19.0M

bought $0, sold $19.0M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+29%

246 13F filers vs 191

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

84%

74.2M shares held by 13F filers (30 Sep 2026) of 87.9M outstanding (31 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

6.5%

5.7M shares sold short (30 Oct 2026) of 87.9M outstanding (31 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.5

5.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-22%

7.3M shares sold short in the report before, 5.7M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

55%

55% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 52%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+57%

$72.9M vs $46.3M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+13%

$1.4M vs $1.2M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$380K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

17

17 articles in the last 7 days; its usual week has 1.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

11×

17 articles in the last 7 days; its usual week has 1.5.

Price $46.69 on 20 Nov 2026, +69% over 12 months (12-month range $20.49 to $60.53)

  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $146.8M in the last 12 months (the 12 months before: $0).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 12 published in the last 12 months, +140% on the 12 months before.
Revenue per quarter. Revenue $72.9M in the latest quarter, +57% on a year earlier.
Capital spending per quarter. Capital spending $1.4M in the latest quarter, +13% on a year earlier.
Institutional holders (13F filers). 246 13F filers reported holding it in the latest 13F quarter, +186% on a year earlier.
Lobbying spend. Lobbying spend: $380K published in the last 12 months, +8.6% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
19 Mar 2026Lobbying filingnew lobbying registration (KOUNTOUPES DENHAM CARR & REID, LLC)
21 Jan 2026Lobbying filinglobbying engagement terminated (DB3, LLC (FKA THE DASCHLE GROUP))
14 Jan 2026Lobbying filinglobbying engagement terminated (BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ)
25 Aug 20258-K and other filingsA major agreement ended
6 Aug 20258-K and other filingsRegistered new securities for sale (S-1)
1 Aug 20258-K and other filingsRegistered new securities for sale (S-1)
17 Jul 20258-K and other filingsRegistered new securities for sale (S-1)
3 Jul 2025Lobbying filinglobbying engagement terminated (in-house)
14 Mar 2024Lobbying filingnew lobbying registration (DB3, LLC (FKA THE DASCHLE GROUP))
29 Jun 2022Lobbying filingnew lobbying registration (in-house)
Insider net buying (open market)
Month from 1 Dec 2025: $1.1M published
Month from 1 Feb 2026: -$58.5M published
Month from 1 Mar 2026: -$2.4M published
Month from 1 Apr 2026: -$2.2M published
Month from 1 May 2026: -$59.8M published
Month from 1 Jun 2026: -$2.0M published
Month from 1 Jul 2026: -$863K published
Month from 1 Aug 2026: -$4.5M published
Month from 1 Sep 2026: -$7.8M published
Month from 1 Oct 2026: -$3.2M published
Month from 1 Nov 2026: -$6.6M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 3 published
Quarter from 1 Apr 2022: 2 published
Quarter from 1 Jul 2022: 2 published
Quarter from 1 Oct 2022: 2 published
Quarter from 1 Jan 2023: 1 published
Quarter from 1 Jul 2023: 3 published
Quarter from 1 Oct 2023: 2 published
Quarter from 1 Apr 2024: 1 published
Quarter from 1 Jul 2024: 1 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Apr 2025: 1 published
Quarter from 1 Jul 2025: 2 published
Quarter from 1 Oct 2025: 2 published
Quarter from 1 Jan 2026: 1 published
Quarter from 1 Apr 2026: 3 published
Quarter from 1 Jul 2026: 6 published
Quarter from 1 Oct 2026: 2 published
Revenue per quarter
Quarter ended 30 Jun 2024: $31.1M; public on 20 Sep 2025
Quarter ended 30 Sep 2024: $32.9M; public on 13 Nov 2025
Quarter ended 31 Dec 2024: $35.0M; public on 19 Mar 2026
Quarter ended 31 Mar 2025: $37.2M; public on 15 May 2026
Quarter ended 30 Jun 2025: $43.4M, +40% on a year earlier; public on 20 Sep 2025
Quarter ended 30 Sep 2025: $46.3M, +41% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $49.1M, +40% on a year earlier; public on 19 Mar 2026
Quarter ended 31 Mar 2026: $52.6M, +41% on a year earlier; public on 15 May 2026
Quarter ended 30 Jun 2026: $64.1M, +48% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $72.9M, +57% on a year earlier; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 30 Sep 2024: $1.0M; public on 13 Nov 2025
Quarter ended 31 Dec 2024: $332K; public on 19 Mar 2026
Quarter ended 31 Mar 2025: $1.1M; public on 15 May 2026
Quarter ended 30 Jun 2025: $790K; public on 20 Sep 2025
Quarter ended 30 Sep 2025: $1.2M, +21% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $1.9M, +472% on a year earlier; public on 19 Mar 2026
Quarter ended 31 Mar 2026: $1.9M, +72% on a year earlier; public on 15 May 2026
Quarter ended 30 Jun 2026: $1.9M, +144% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $1.4M, +13% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
30 Sep 2025 report: 86; public on 14 Nov 2025
31 Dec 2025 report: 110; public on 17 Feb 2026
31 Mar 2026 report: 166; public on 15 May 2026
30 Jun 2026 report: 191; public on 14 Aug 2026
30 Sep 2026 report: 246; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $130K published
Quarter from 1 Apr 2022: $130K published
Quarter from 1 Jul 2022: $110K published
Quarter from 1 Oct 2022: $110K published
Quarter from 1 Jan 2023: $110K published
Quarter from 1 Apr 2023: $120K published
Quarter from 1 Jul 2023: $120K published
Quarter from 1 Oct 2023: $110K published
Quarter from 1 Apr 2024: $120K published
Quarter from 1 Jul 2024: $90K published
Quarter from 1 Oct 2024: $90K published
Quarter from 1 Jan 2025: $80K published
Quarter from 1 Apr 2025: $90K published
Quarter from 1 Jul 2025: $90K published
Quarter from 1 Oct 2025: $90K published
Quarter from 1 Jan 2026: $90K published
Quarter from 1 Apr 2026: $90K published
Quarter from 1 Jul 2026: $100K published
Quarter from 1 Oct 2026: $100K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $4.2M (19 Nov 2026), 3.0× its normal reading; higher than 94% of its own history.
  • Insider net buying (open market): Insiders sold a net $146.8M in the last 12 months (the 12 months before: $0).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 12 published in the last 12 months, +140% on the 12 months before.
  • Revenue per quarter: Revenue $72.9M in the latest quarter, +57% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 34 insider trades

Last 90 days: 12 sales, $19.0M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Nov 2026Campbell RogersChief Medical OfficerSellplanned in advance (10b5-1); after exercising options111,412$37.86$4.2MForm 4
10 Nov 2026John C.m. FarquharChief Executive OfficerSellplanned in advance (10b5-1); after exercising options38,900$55.74$2.2MForm 4
10 Nov 2026Vikram VergheseChief Financial OfficerSellplanned in advance (10b5-1)3,587$53.15$191KForm 4
26 Oct 2026Campbell RogersChief Medical OfficerSellplanned in advance (10b5-1); after exercising options23,933$55.01$1.3MForm 4
14 Oct 2026John C.m. FarquharChief Executive OfficerSellplanned in advance (10b5-1)38,900$49.57$1.9MForm 4
21 Sep 2026Campbell RogersChief Medical OfficerSellplanned in advance (10b5-1); after exercising options19,682$50.15$987KForm 4
18 Sep 2026Vikram VergheseChief Financial OfficerSellplanned in advance (10b5-1)24,345$50.55$1.2MForm 4
15 Sep 2026Vikram VergheseChief Financial OfficerSellplanned in advance (10b5-1)34,975$50.08$1.8MForm 4

246 institutions reported shares at the end of Q3 2026, 84% of the shares outstanding; 78 opened a position, 24 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.6.0M6.87%$300.5M+843K+16%
Wellington Management Group LLP5.5M6.31%$276.0M-2.3M-29%
FMR LLC (Fidelity)5.5M6.25%$273.2M+670K+14%
Bain Capital Life Sciences Investors, LLC4.4M5.06%$221.3M-4.0M-47%
Vanguard Portfolio Management LLC3.7M4.23%$185.0M+135K+3.8%
Vanguard Capital Management LLC3.3M3.77%$165.0M+562K+20%
Invesco Ltd.2.7M3.06%$134.0M+395K+17%
Bamco Inc2.5M2.86%$124.9M-715K-22%
D. E. Shaw & Co., Inc.2.1M2.40%$105.0M+2.1M243 times as many
Janus Henderson Group Ltd.1.9M2.21%$96.7M

Company events

All 6 company events

Nothing in 12 months; the latest was filed 25 Aug 2025. Results releases and routine reports are left out.

FiledWhat happenedSource
25 Aug 2025A major agreement ended8-K
6 Aug 2025Registered new securities for sale (S-1)S-1/A
1 Aug 2025Registered new securities for sale (S-1)S-1/A
17 Jul 2025Registered new securities for sale (S-1)S-1
13 Jun 2019Private placement of securities (Form D)$65.0M sold of $100.0M offeredD
4 Dec 2017Private placement of securities (Form D)$90.0M sold of $150.0M offeredD

Reported lobbying spend: $100K in Q3 2026, $100K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
26 Jan 2026NewKountoupes Denham Carr & Reid, LLCfor Heartflow, Inc.Issues related to Medicare reimbursement.Health issues, Medicare/MedicaidFiling
31 Dec 2025EndedDB3, LLC (Fka The Daschle Group)for Heartflow, Inc.Medicare reimbursement issues related to AI-enabled technologyMedicare/MedicaidFiling
31 Dec 2025EndedBaker Donelson Bearman Caldwell & Berkowitzfor Heartflow, Inc.Medicare reimbursement issueMedicare/MedicaidFiling
30 Jun 2025EndedHeartflow, Inc.its own lobbyistsIssues related to physician payments; issues related to Medicare reimbursement; issues related to Medicare reimbursement of AI-enabled technology; S.Con.Res.7 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and settingMedicare/MedicaidFiling
1 Mar 2024NewDB3, LLC (Fka The Daschle Group)for Heartflow, Inc.Medicare reimbursement issuesMedicare/MedicaidFiling
1 Jun 2022NewHeartflow, Inc.its own lobbyistsMedicare reimbursementHealth issues, MED, Medicare/Medicaid, Science/technologyFiling
20 Jul 2020NewSquire Patton Boggsfor Heartflow, Inc.Medicare reimbursement for utilization of new technologies.Health issues, Medicare/MedicaidFiling
1 Apr 2020EndedLee Consulting, Kenneth G.for HeartflowNot statedFiling

The 5 newest of 113 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 19 Mar 2026Lobbying record

    HEARTFLOW, INC.: new lobbying registration (KOUNTOUPES DENHAM CARR & REID, LLC) (dated 26 Jan 2026)

  2. 21 Jan 2026Lobbying record

    HEARTFLOW, INC.: lobbying engagement terminated (DB3, LLC (FKA THE DASCHLE GROUP)) (dated 31 Dec 2025)

  3. 14 Jan 2026Lobbying record

    HEARTFLOW, INC.: lobbying engagement terminated (BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ) (dated 31 Dec 2025)

  4. 18 Dec 2025Insiders record

    Lightcap Jeffrey C (director) bought 40,000 shares of HTFL ($1.1M) (dated 17 Dec 2025)

  5. 25 Aug 2025Filings record

    A major agreement ended

  6. 6 Aug 2025Filings record

    Registered new securities for sale (S-1)

  7. 1 Aug 2025Filings record

    Registered new securities for sale (S-1)

  8. 17 Jul 2025Filings record

    Registered new securities for sale (S-1)

  9. 3 Jul 2025Lobbying record

    HEARTFLOW, INC.: lobbying engagement terminated (in-house) (dated 30 Jun 2025)

  10. 14 Mar 2024Lobbying record

    HEARTFLOW, INC.: new lobbying registration (DB3, LLC (FKA THE DASCHLE GROUP)) (dated 1 Mar 2024)

  11. 29 Jun 2022Lobbying record

    HEARTFLOW, INC.: new lobbying registration (in-house) (dated 1 Jun 2022)

  12. 28 Jul 2020Lobbying record

    HEARTFLOW, INC.: new lobbying registration (SQUIRE PATTON BOGGS) (dated 20 Jul 2020)

  13. 2 Jul 2020Lobbying record

    HEARTFLOW: lobbying engagement terminated (LEE CONSULTING, KENNETH G.) (dated 1 Apr 2020)

  14. 17 Apr 2020Lobbying record

    HEARTFLOW, INC.: lobbying engagement terminated (HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)) (dated 31 Mar 2020)

  15. 17 Apr 2020Lobbying record

    HEARTFLOW, INC.: lobbying engagement terminated (THE CORMAC GROUP, LLC) (dated 31 Jan 2020)

  16. 7 Apr 2020Lobbying record

    HEARTFLOW: lobbying engagement terminated (AMERICAN CAPITOL GROUP) (dated 31 Mar 2020)

  17. 21 Oct 2019Lobbying record

    HEARTFLOW, INC.: new lobbying registration (BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ) (dated 1 Jun 2019)

  18. 13 Jun 2019Filings record

    Private placement of securities (Form D)

  19. 29 Jan 2019Lobbying record

    HEARTFLOW: new lobbying registration (LEE CONSULTING, KENNETH G.) (dated 1 Nov 2018)

  20. 29 Jan 2019Lobbying record

    HEARTFLOW: lobbying engagement terminated (THE BENNETT CONSULTING GROUP) (dated 1 Nov 2018)

  21. 20 Jul 2018Lobbying record

    HEARTFLOW: lobbying engagement terminated (KING & SPALDING LLP) (dated 30 Jun 2018)

  22. 22 Jun 2018Lobbying record

    HEARTFLOW: new lobbying registration (AMERICAN CAPITOL GROUP) (dated 1 Jun 2018)

  23. 18 Jan 2018Lobbying record

    HEARTFLOW, INC.: new lobbying registration (THE CORMAC GROUP, LLC) (dated 1 Oct 2017)

  24. 8 Jan 2018Lobbying record

    BENNETT GROUP ON BEHALF OF HEARTFLOW: lobbying engagement terminated (AMERICAN CAPITOL GROUP) (dated 29 Dec 2017)

  25. 4 Dec 2017Filings record

    Private placement of securities (Form D)

  26. 19 Oct 2017Lobbying record

    BENNETT GROUP ON BEHALF OF HEARTFLOW: new lobbying registration (AMERICAN CAPITOL GROUP) (dated 2 Oct 2017)

  27. 16 Oct 2017Lobbying record

    HEARTFLOW: new lobbying registration (THE BENNETT CONSULTING GROUP) (dated 4 Oct 2017)

  28. 28 Jul 2017Lobbying record

    HEARTFLOW, INC.: new lobbying registration (HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)) (dated 6 Jul 2017)

  29. 24 Oct 2016Lobbying record

    HEARTFLOW: new lobbying registration (KING & SPALDING LLP)

Not listed: 46 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001464521
Ticker
HTFL
Domain
heartflow.com
Employer name
HEARTFLOW, INC. (1 unverified)
Hq location
CA|SAN FRANCISCO|94105 (1 unverified)
Lobbying client
bennett group on behalf of heartflow, heartflow
Name
Cardiovascular Simulation, Inc., Company Name, Heartflow, Inc., HeartFlow Japan G.K and 1 more
Uei
HT8QH17PXK29, XEM7DMQ16R45
  • DOL H-1B labor condition applications and PERM certifications218 data points14 Oct 2019 to 7 Sep 2026
  • Federal lobbying disclosures (LDA)22 records, 118 data points24 Oct 2016 to 30 Sep 2026
  • SEC Form 13F institutional holdings45 data points30 Sep 2025 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)19 records4 Dec 2017 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)180 data points31 Dec 2022 to 31 Oct 2026
  • SEC Form 4 insider transactions34 records, 128 data points17 Dec 2025 to 19 Nov 2026
  • FINRA short interest (twice monthly)89 data points15 Aug 2025 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)650 data points8 Aug 2025 to 20 Nov 2026
  • USASpending.gov federal awards15 data points28 Jul 2008 to 4 Aug 2011